SUMMARY
The Fund reported a pleasing return of 13.5% during the month due mostly to a 114% return in the Fund’s largest holding, Australian radiopharmaceutical company Telix. Helping markets was the announcement by Pfizer of strong Covid vaccine study results, which generally boosted sentiment, although this was not a substantial driver of gains in the Fund.